.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The new interim trade agreement framework has significantly reshaped the commercial landscape for the India US Medical Devices sector. As India agrees to ease non-tariff barriers for U.S.-made medical devices, the domestic industry is strongly pushing for reciprocal treatment. This necessary balance ensures fair trade and sustained growth for Indian manufacturers. Consequently, both nations released a joint statement outlining these key changes.
India is committed to eliminating restrictive import licensing procedures which previously delayed market access for U.S. medical devices. This move addresses a long-standing barrier to trade. Furthermore, the statement provides a six-month timeline. Within this window, India will update its stance on accepting U.S.-developed or international standards, including testing requirements, for U.S. exports in identified market sectors. This regulatory harmonization aims to streamline the import process. Himanshu Baid, MD of Poly Medicure Ltd., views this interim agreement as a strong opportunity. Specifically, he highlights the potential for deeper technology collaboration in high-value segments like medical imaging, where US companies possess established strengths.
While welcoming the agreement, the Association of Indian Medical Device Industry (AiMeD) Coordinator, Rajiv Nath, seeks reciprocal treatment. Notably, he argues that import licenses for U.S. devices are already processed faster than those for Indian manufacturers. Therefore, Indian firms face mandatory inspections while overseas companies do not. Moreover, trade data shows significant asymmetry. The U.S. leads imports into India at ₹14,000 crore, surpassing China’s ₹12,000 crore, while India's exports stand at approximately $750 million. In addition, the US FDA’s preference for ACSA over NABL labs further exacerbates this asymmetry. Ultimately, the industry wants mutually advantageous trade to empower both nations' innovations.
The U.S. administration already agreed to slash tariffs on Indian medical devices. These tariffs dropped sharply from 50 per cent to 18 per cent under the interim deal. Consequently, this change immediately positions India’s domestic industry below its international competitors, most notably China, which faces a headline tariff rate of 37 per cent. As a result, this tariff reduction acts as a game-changer for Indian manufacturers. It cuts export costs and unlocks billions in the U.S. market, aligning with global supply chain shifts like 'China+1'. With US import tariffs now at 18 per cent, Indian MedTech exporters gain a meaningful competitive advantage in one of the world's most sophisticated healthcare markets. Nevertheless, India still meets 70 per cent of its medical device requirements through imports, highlighting a high dependence due to limited domestic manufacturing capacity for high-end equipment.
The trade predominantly involves distinct types of products. Top imports from the U.S. include sophisticated items. For example, these items include diagnostic reagent kits, linear ultrasound devices, and various software-based devices. Meanwhile, India’s top exports focus on high-volume products. Specifically, these products are items such as bandages, waste disposable bags, and headgears.
Q1: What is the primary change for US medical devices entering India?
India agrees to ease non-tariff barriers, specifically eliminating restrictive import licensing procedures that previously delayed market access.
Q2: How does the new trade agreement benefit Indian medical device manufacturers?
The US reduced tariffs on Indian medical devices from 50% to 18%. Therefore, this significantly enhances their competitive advantage in the U.S. market.
Q3: What reciprocal treatment is the Indian medical device industry seeking?
The domestic industry seeks reciprocal fairness in regulatory processes, such as acceptance of NABL labs by the US FDA, to balance the trade asymmetry.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India eases non-tariff barriers for US medical device imports, while the US slashes tariffs on Indian exports to 18%, sparking industry calls for reciprocal...
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
